Glaxo’s Bitter Pill—Tax Department Delivers a ₹30.7 Million Wake-Up Call

GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharma) received a tax demand order of ₹30.7 million (₹3.07 crore) from Indian tax authorities, according to a regulatory filing as of June 19, 2025. The company has not yet discussed the assessment year or rationale for the demand, but is presently reviewing the notice and deciding on its course of action.

 

This comes on the heels of a robust Q3 FY25 financial performance by GSK Pharma, wherein it posted:

The firm's franchise brands—Augmentin, Trelegy, and Shingrix—inched higher on market share, bolstering its leadership in general medicines and vaccines.

 

Though tax demand could spur short-term compliance concerns, experts feel GSK's good fundamentals and product tailwind will still keep investor sentiment in place.

 

Sources: CNBC TV18, BSE India, Moneycontrol